Document is current
Any future updates will be listed below
-
Authors
Raimondo, Maria G. https://orcid.org/0000-0003-2020-6711
Mohammadian, Hashem https://orcid.org/0000-0003-2565-2702
Angeli, Mario R. https://orcid.org/0000-0002-2911-4269
Alivernini, Stefano https://orcid.org/0000-0002-7383-4212
Fedorchenko, Vladyslav
Huang, Kaiyue
Demmler, Richard
Rhein, Peter
Xu, Cong
Li, Yi-Nan https://orcid.org/0000-0001-8934-9361
Micheroli, Raphael https://orcid.org/0000-0002-8918-7304
Winter, Zoltán https://orcid.org/0000-0003-4119-9637
Rigau, Aleix Rius
Anchang, Charles G.
Soare, Alina
Luber, Markus https://orcid.org/0000-0003-1895-5481
Labinsky, Hannah
Chang, Jiyang
Günther, Claudia
Fearon, Ursula
Veale, Douglas J. https://orcid.org/0000-0003-2802-4971
Ciccia, Francesco https://orcid.org/0000-0002-9352-1264
Rech, Jürgen https://orcid.org/0000-0002-2569-2029
Sticherling, Michael
Bäuerle, Tobias
Distler, Jörg H. W.
Kurowska-Stolarska, Mariola S. https://orcid.org/0000-0003-2124-7777
Mack, Matthias https://orcid.org/0000-0002-3157-7262
Ekici, Arif B. https://orcid.org/0000-0001-6099-7066
Croft, Adam P. https://orcid.org/0000-0002-9487-0511
Distler, Oliver
Maric, Hans M. https://orcid.org/0000-0002-2719-4752
Ospelt, Caroline https://orcid.org/0000-0002-9151-4650
Cañete, Juan D. https://orcid.org/0000-0003-2606-0573
D’Agostino, Maria A.
Schett, Georg https://orcid.org/0000-0001-8740-9615
Rauber, Simon https://orcid.org/0000-0001-8306-9334
Ramming, Andreas https://orcid.org/0000-0002-7003-501X
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 20 October 2025
First Online: 2 January 2026
Competing interests
: P.R. is employed by Cytek Biosciences, the maker of the Amnis brand ImageStream, which was used in this study. O.D. declares consultancy relationships with and/or has received research funding from and/or has served as a speaker for the following companies in the area of rheumatology in the past three calendar years: 4P-Pharma, Abbvie, Acepodia, Aera, AnaMar, Anaveon, Argenx, AstraZeneca, Boehringer Ingelheim, BMS, Calluna, Cantargia, CSL Behring, EMD Serono, Galderma, Galapagos, Gossamer, Hemetron, Innovaderm, Janssen, Lilly, MSD Merck, Nkarta, Novartis, Oorja Bio, Orion, Pilan, Prometheus, Quell, Redxpharma, Scleroderma Research Foundation, Sumitomo, Topadur, UCB and Umlaut bio. O.D. has a patent ‘mir-29 for the treatment of systemic sclerosis’ (US8247389, EP2331143) and is cofounder of CITUS. The other authors declare no competing interests.
